申请人:Wuelfing; Johann A.
公开号:US04396622A1
公开(公告)日:1983-08-02
Pharmaceutical compositions which comprise a compound of the formula (I): ##STR1## or a salt thereof wherein NR.sub.2 represents a piperidyl, pyrrolidyl, morpholino or N-methyl-piperazyl group any of which may substituted by one or two methyl groups; R.sup.1 represents fluorine, chlorine, bromine, iodine, lower alkoxyl, hydroxyl, acetoxyl, nitro, cyano, amino, dimethylamino, lower alkyl, trifluoromethyl, methylthio, ethylthio, methoxycarbonyl, ethoxycarbonyl, acetamido or carboxamido; R.sup.2 represents hydrogen, fluorine, chlorine, bromine, iodine, lower alkoxyl, hydroxyl, lower alkyl; R.sup.3 represents hydrogen, chlorine or lower alkyl; or R.sup.1 and R.sup.2 when on adjacent carbon atoms may together represent a polymethylene group containing from 3 to 5 carbon atoms; and n is 2, 3 or 4; and a pharmaceutically acceptable carrier, compounds of formula (I) except those wherein R.sup.1 is a 2-methoxyl group, and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine, a process for the preparation of compounds of the formula (I) and 2,4-dimethyl-1-[2-(4-bromophenylsulphonamido)ethyl]pyrrolidine and 2,4-dimethyl-1[2-(4-iodophenylsulphonamido)ethyl]pyrrolidine as antiarrhythymic agents.
含有化合物(I)的制药组合物,化合物(I)的结构式如下:##STR1##或其盐,其中NR.sub.2代表
哌啶基、
吡咯烷基、吗啉基或
N-甲基哌嗪基基团,其中任何一个基团可以被一个或两个甲基基团取代;R.sup.1代表
氟、
氯、
溴、
碘、低碳基氧基、羟基、乙酰氧基、硝基、
氰基、
氨基、二甲基
氨基、低碳基、三
氟甲基、甲
硫基、乙
硫基、甲氧基羰基、乙氧基羰基、乙酰胺基或羧酰胺基;R.sup.2代表氢、
氟、
氯、
溴、
碘、低碳基氧基或低碳基;R.sup.3代表氢、
氯或低碳基;或者当R.sup.1和R.sup.2在相邻的碳原子上时,它们可以一起表示含有3到5个碳原子的多亚甲基基团;n为2、3或4;并且与药物可接受载体一起使用,化合物(I)除R.sup.1为2-甲氧基基团的化合物以及2,4-二甲基-1-[2-(4-
溴苯磺酰胺)乙基]
吡咯烷和2,4-二甲基-1-[2-(4-
溴苯磺酰胺)乙基]
吡咯烷,以及化合物(I)和2,4-二甲基-1-[2-(4-
碘苯磺酰胺)乙基]
吡咯烷作为
抗心律失常药物的制备方法。